Virtual EA reviews from pharmaceutical and biotech company CEOs reveal patterns that generic review aggregators miss. When executives at clinical-stage and commercial-stage companies evaluate their EA support, the criteria that determine satisfaction are specific to the industry: regulatory calendar management, investor communications handling, confidentiality standards, and the ability to operate effectively in a technically complex environment.
Understanding what pharmaceutical and biotech CEOs actually report about their virtual EA experiences helps you set expectations and choose more wisely.
What CEOs Report: Common Themes in Positive Reviews
Regulatory Calendar Management
The most frequently cited positive experience involves EAs who take ownership of the regulatory calendar without requiring constant supervision. Pharmaceutical CEOs describe the value of an EA who anticipates preparation time for FDA meetings, builds in buffer before submission deadlines, and flags potential scheduling conflicts before they become problems.
One pattern that emerges consistently: CEOs who invested time in thorough onboarding, specifically dedicating five to ten hours to walking their EA through the regulatory calendar and key stakeholder relationships, report dramatically better experiences than those who expected an EA to figure out the context independently.
Investor Relations Coordination
CEOs managing active investor programs describe their EAs as essential to maintaining the quality and consistency of investor interactions. The positive reviews in this area describe EAs who handle meeting scheduling, travel logistics, briefing preparation coordination, and follow-up tracking seamlessly, creating an investor experience that reflects well on the company’s professionalism.
For a biotech CEO managing relationships with 20 to 40 institutional investors alongside a clinical development program, this coordination function is operationally significant.
Confidentiality and Discretion
Pharmaceutical and biotech CEOs consistently emphasize discretion as a defining quality in their best EA relationships. The executives who report the highest satisfaction levels describe EAs who understand what information to share, what to protect, and how to handle sensitive communications without creating exposure.
This quality is difficult to screen for in advance, but it shows up repeatedly as the deciding factor between CEOs who view their EA as a genuine asset and those who feel perpetually concerned about information management.
What CEOs Report: Common Themes in Negative Reviews
Slow Ramp-Up and Knowledge Gaps
The most common source of dissatisfaction is an EA who lacks pharmaceutical or biotech context and takes too long to become effective. CEOs describe frustration with assistants who do not understand FDA terminology, cannot communicate credibly with scientific or regulatory staff, or make scheduling errors because they do not understand the significance of specific meeting types.
The solution is not necessarily to hire only EAs with pharmaceutical backgrounds. It is to invest in structured onboarding and to choose a service that prepares their EAs for specialized industry environments.
Communication Standards That Fall Short
Several pharmaceutical CEOs describe experiences where their EA’s written communication did not meet the standard expected in executive-level pharmaceutical operations. Emails to regulatory contacts, investor relations staff, and board members require precision and a certain register. When an EA communicates below that standard, it creates work for the CEO rather than eliminating it.
Before committing to any EA service or individual EA, request writing samples and references from executive-level clients in regulated industries. This is a reasonable screening request that any quality service should accommodate.
Scope Creep and Contract Issues
Some CEOs describe frustration with service contracts that seemed clear at signing but became contentious when needs expanded. An EA engaged for calendar management and travel logistics who suddenly becomes involved in board prep and investor day coordination may trigger hourly overage charges or scope disputes.
This problem is avoidable. Define scope explicitly at the outset, including the categories of work covered, the hours included per week, and the rate for hours above that threshold.
Questions to Ask Service Providers Before Signing
Based on patterns in pharmaceutical CEO feedback, these are the questions that most effectively separate high-quality services from adequate ones.
On Industry Knowledge: Do you screen EAs for life sciences or pharmaceutical experience? What percentage of your current EA pool has supported executives in regulated industries?
On Confidentiality: What background checks do you conduct? What NDAs govern the relationship? What happens if my EA mishandles confidential information?
On Replacement Speed: What is your average replacement turnaround time? Have you placed replacements for pharmaceutical clients during critical regulatory periods?
On Onboarding Support: What resources do you provide to help my EA get up to speed on my operation quickly? Do you have templates or frameworks for pharmaceutical client onboarding?
On Communication Standards: Can I review work samples from EAs you are considering matching me with? Can I speak with current pharmaceutical or biotech CEO clients as references?
For a comprehensive view of which services receive the best marks from pharmaceutical executives, see best virtual EA for pharma. For a comparison of part-time service models, part-time EA for pharma covers that segment in detail.
The Research Context for EA Satisfaction
Research from Harvard Business Review identifies a consistent pattern: executives who report high satisfaction with their administrative support also report higher personal productivity, better quality of strategic decision-making, and lower chronic stress related to operational management. The relationship is causal, not coincidental. Effective support changes how an executive operates.
In pharmaceutical and biotech, the stakes of that relationship are amplified by the complexity and regulatory significance of the CEO’s responsibilities. A well-matched EA does not just save time. It improves the quality of your leadership.
Making Sense of Online Reviews
Online review platforms for EA services often reflect general business clients rather than pharmaceutical executives specifically. Positive reviews on Clutch, G2, or Google may describe experiences that do not map to what a pharma CEO needs.
When you read reviews for any service you are considering, filter specifically for: regulated industry experience, executive-level client relationships, comments about confidentiality and discretion, and feedback about how the service handled issues when they arose.
The best evidence is not aggregated star ratings. It is direct conversations with pharmaceutical or biotech executives who have used the service in situations comparable to yours.
Conclusion
Virtual EA reviews from pharmaceutical and biotech company CEOs consistently point to the same success factors: pharmaceutical context awareness, high communication standards, strong confidentiality protocols, and an EA who takes initiative rather than waiting for instructions. The negative patterns are equally consistent: industry knowledge gaps, slow ramp-up, and scope ambiguity. Use this framework to evaluate any service you consider, and prioritize direct references from life sciences executives over general platform reviews.
Related Reading
For further context, explore Virtual EA Reviews From Automotive Company CEOs and Virtual EA Reviews From Construction & Architecture Company CEOs.